Non-Franchise (NOF) - R&D: payments to doctors
Payments that named Non-Franchise (NOF) - R&D as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Baxter Healthcare?
Baxter Healthcare reported the most payments naming Non-Franchise (NOF) - R&D. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $63K
- Providers
- 2
- Transactions
- 8
- Average per transaction
- $7,825
The per-transaction average — $7,825 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2 providers the average total is $31,300, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Baxter Healthcare | $62,600 | 100.0% |
Other products from Baxter Healthcare
The company that reported the most payments naming Non-Franchise (NOF) - R&D also reports against these.
- FLOSEAL$3,267,702
- TISSEEL$2,931,610
- Hillrom - RetinaVue 700 Imager$2,479,908
- Hillrom - RetinaVue Network$2,476,120
- Renal - PD$1,364,559
- No Related Product$1,269,282
- Renal - Acute$906,678
- PERI-STRIPS DRY$703,404
- COSEAL$677,488
- SUPRANE$571,742